196 related articles for article (PubMed ID: 33408788)
1. A general Fc engineering platform for the next generation of antibody therapeutics.
Chen D; Zhao Y; Li M; Shang H; Li N; Li F; Wang W; Wang Y; Jin R; Liu S; Li X; Gao S; Tian Y; Li R; Li H; Zhang Y; Du M; Cao Y; Zhang Y; Li X; Huang Y; Hu LA; Li F; Zhang H
Theranostics; 2021; 11(4):1901-1917. PubMed ID: 33408788
[No Abstract] [Full Text] [Related]
2. Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.
Liu Z; Gunasekaran K; Wang W; Razinkov V; Sekirov L; Leng E; Sweet H; Foltz I; Howard M; Rousseau AM; Kozlosky C; Fanslow W; Yan W
J Biol Chem; 2014 Feb; 289(6):3571-90. PubMed ID: 24311787
[TBL] [Abstract][Full Text] [Related]
3. Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity.
Elter A; Yanakieva D; Fiebig D; Hallstein K; Becker S; Betz U; Kolmar H
Front Immunol; 2021; 12():715719. PubMed ID: 34413859
[TBL] [Abstract][Full Text] [Related]
4. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.
Zhang D; Goldberg MV; Chiu ML
J Biol Chem; 2016 Dec; 291(53):27134-27146. PubMed ID: 27856634
[TBL] [Abstract][Full Text] [Related]
5. Engineered aglycosylated full-length IgG Fc variants exhibiting improved FcγRIIIa binding and tumor cell clearance.
Jo M; Kwon HS; Lee KH; Lee JC; Jung ST
MAbs; 2018; 10(2):278-289. PubMed ID: 29173039
[TBL] [Abstract][Full Text] [Related]
6. Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant.
Mimoto F; Igawa T; Kuramochi T; Katada H; Kadono S; Kamikawa T; Shida-Kawazoe M; Hattori K
MAbs; 2013; 5(2):229-36. PubMed ID: 23406628
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.
Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K
Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029
[TBL] [Abstract][Full Text] [Related]
8. Optimal combination of beneficial mutations for improved ADCC effector function of aglycosylated antibodies.
Yoon HW; Jo M; Ko S; Kwon HS; Lim CS; Ko BJ; Lee JC; Jung ST
Mol Immunol; 2019 Oct; 114():62-71. PubMed ID: 31336250
[TBL] [Abstract][Full Text] [Related]
9. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
[TBL] [Abstract][Full Text] [Related]
10. Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131).
Mimoto F; Katada H; Kadono S; Igawa T; Kuramochi T; Muraoka M; Wada Y; Haraya K; Miyazaki T; Hattori K
Protein Eng Des Sel; 2013 Oct; 26(10):589-98. PubMed ID: 23744091
[TBL] [Abstract][Full Text] [Related]
11. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
[TBL] [Abstract][Full Text] [Related]
12. An antibody Fc engineered for conditional antibody-dependent cellular cytotoxicity at the low tumor microenvironment pH.
Liu Y; Lee AG; Nguyen AW; Maynard JA
J Biol Chem; 2022 Apr; 298(4):101798. PubMed ID: 35248534
[TBL] [Abstract][Full Text] [Related]
13. Differential regulation of human monocytes and NK cells by antibody-opsonized tumors.
Yin J; Albers AJ; Smith TS; Riddell GT; Richards JO
Cancer Immunol Immunother; 2018 Aug; 67(8):1239-1250. PubMed ID: 29855696
[TBL] [Abstract][Full Text] [Related]
14. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.
Monnet C; Jorieux S; Souyris N; Zaki O; Jacquet A; Fournier N; Crozet F; de Romeuf C; Bouayadi K; Urbain R; Behrens CK; Mondon P; Fontayne A
MAbs; 2014; 6(2):422-36. PubMed ID: 24492301
[TBL] [Abstract][Full Text] [Related]
15. An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa
Kang TH; Lee CH; Delidakis G; Jung J; Richard-Le Goff O; Lee J; Kim JE; Charab W; Bruhns P; Georgiou G
Front Immunol; 2019; 10():562. PubMed ID: 30984171
[TBL] [Abstract][Full Text] [Related]
16. Charge variant analysis of proposed biosimilar to Trastuzumab.
Dakshinamurthy P; Mukunda P; Prasad Kodaganti B; Shenoy BR; Natarajan B; Maliwalave A; Halan V; Murugesan S; Maity S
Biologicals; 2017 Mar; 46():46-56. PubMed ID: 28087106
[TBL] [Abstract][Full Text] [Related]
17. Engineered antibody Fc variants with enhanced effector function.
Lazar GA; Dang W; Karki S; Vafa O; Peng JS; Hyun L; Chan C; Chung HS; Eivazi A; Yoder SC; Vielmetter J; Carmichael DF; Hayes RJ; Dahiyat BI
Proc Natl Acad Sci U S A; 2006 Mar; 103(11):4005-10. PubMed ID: 16537476
[TBL] [Abstract][Full Text] [Related]
18. Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells.
Jung ST; Reddy ST; Kang TH; Borrok MJ; Sandlie I; Tucker PW; Georgiou G
Proc Natl Acad Sci U S A; 2010 Jan; 107(2):604-9. PubMed ID: 20080725
[TBL] [Abstract][Full Text] [Related]
19. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
[TBL] [Abstract][Full Text] [Related]
20. Importance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other Fcγ Receptors.
Isoda Y; Yagi H; Satoh T; Shibata-Koyama M; Masuda K; Satoh M; Kato K; Iida S
PLoS One; 2015; 10(10):e0140120. PubMed ID: 26444434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]